|
Safety and Tolerability Study of FPTI in Patients With Leukemia Clinical Trials References presented on Clinical Trials Search isn't meant to be a substitute for proven healthcare advice, trips or professional assistance using a genuine physician. We are not docs. Always confer with your physician about Safety and Tolerability Study of FPTI in Patients With Leukemia conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. Safety and Tolerability Study of FPTI in Patients With Leukemia Clinical research trials and Safety and Tolerability Study of FPTI in Patients With Leukemia healthcare trials happen in hundreds of localities throughout the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually evaluate the potency of new drugs. The propose of the studies / projects is to answer particular human health questions. Clinical trials are a popular way for mDs, government agencies, and private sector companies to detect cures for all sorts of conditions, such as Safety and Tolerability Study of FPTI in Patients With Leukemia. Safety and Tolerability Study of FPTI in Patients With Leukemia Clinical Trials and other clinical trials allow volunteers to acquire healthcare treatment choices before they are available to the general public. Some times the subjects recieve professional assistance for free, and every now and again they are compensated for their time. Sometimes there is a cost for a Safety and Tolerability Study of FPTI in Patients With Leukemia clinical trial. Subjects frequently obtain the most expert healthcare possible for their Safety and Tolerability Study of FPTI in Patients With Leukemia condition. Risks are a reality, nevertheless, and can include more or frequent doctor trips, medical risks (possibly life-threatening), and/or the treatment being uneffective. Trials are federally governed with stern guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "S" Clinical Trials Conditions > Safety and Tolerability Study of FPTI in Patients With Leukemia  Safety and Tolerability Study of FPTI in Patients With Leukemia
Safety and Tolerability Study of FPTI in Patients With Leukemia
For Condition: Leukemia, Lymphocytic,Blast Crisis,Leukemia, Myeloid, Chronic,Leukemia,Myelodysplastic Syndromes
Status: No longer recruiting
Sponsor(s): Schering-Plough ,
Synopsis: The purpose of this study is to determine the safety and tolerability of an oral Farnesyl Protein Transferase Inhibitor (SCH 66336) as a single agent in patients with Advanced Myelodysplastic Syndrome, Acute Myelogenous Leukemia, Chronic Myelogenous Leukemia in Blast Crisis, or Acute Lymphoblastic Leukemia.
Details:
Eligibility:
Study Type: Interventional, Treatment, Non-Randomized, Open Label, Dose Comparison, Parallel Assignment, Safety Study
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: INCLUSION Criteria: - Pathologically documented chronic myelogenous leukemia in blast crisis, myelodysplasia, acute myelogenous leukemia, or acute lymphocytic leukemia. - Life expectancy of 12 weeks or greater. - ECOG Performance Status less than or equal to 2. - Meets protocol requirements for specified laboratory values. - No manifestations of a malabsorption syndrome. EXCLUSION Criteria: - Patients who have received more than three chemotherapy regimens for more than three recurrences of the disease. - Poor medical risks because of nonmalignant systemic disease as well as those with active uncontrolled conditions. - Patients who have received investigational therapy of any type within 30 days prior to administration.
Total Enrollment: 90
Location and Contact Information:
Glasgow Royal Infirmary
Glasgow, ,
United Kingdom
Robert H. Lurie Comprehensive Cancer Center of Northwestern University
Chicago, Illinois,
United States
University of Newcastle upon Tyne
Newcastle upon Tyne, ,
United Kingdom
C.H.U. de Bordeaux, Groupe Hospitalier Bordeaux Sud - Haut Leveque
Pessac, ,
France
Medicinsk-Haematologisk Afd. B
Aarhus C, ,
Denmark
Arizona Cancer Center
Tucson, Arizona,
United States
University of Minnesota
Minneapolis, Minnesota,
United States
Seattle Cancer Care Alliance
Seattle, Washington, 98109-1023
United States
C.H.R.U. de Tours, Hospital Bretonneau
Tours, ,
France
C.H.U. de Strabourg, Hopital Civil
Strasbourg, ,
France
Dana Farber Cancer Institute
Boston, Massachusetts,
United States
Cross Cancer Institute
Edmonton, Alberta,
Canada
Weill Cornell Medical College
New York City, New York,
United States
Dana Farber Cancer Institute
Boston, Massachusetts,
United States
Unitersita di Bologna
Bologna, ,
Italy
Oregon Health Sciences University
Portland, Oregon,
United States
University Hosipital
Uppsala, ,
Sweden
C.H.U. Hospital de la Miletrie
Poitiers, ,
France
MD Anderson Cancer Center Dept of Leukemia
Houston, Texas,
United States
C.H.U. Hopital de la Miletrie
Poitiers, , 86021
France
Princess Margaret Hospital
Toronto, ,
Canada
Hopital Haut Leveque
Pessac Cedex, , 33604
France
University of Texas
Houston, Texas,
United States
Additional Information:
Study ID Numbers: P00701;
Study Start Date: June 2001
Record last reviewed: May 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00034684
Other Leukemia, Lymphocytic Studies:
1. Phenylbutyrate and Tretinoin in Treating Patients With Hematologic Cancer
2. Low-Dose Decitabine Compared With Standard Supportive Care in Treating Older Patients With Myelodysplastic Syndrome
3. VNP40101M and Cytarabine in Treating Patients With Hematologic Malignancies
4. Efficacy and safety study of CC-5013 monotherapy in subjects with myelodysplastic syndromes
5. Genetic Study of Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndromes
Related Studies:
Other Leukemia, Lymphocytic Clinical Trials
Other Massachusetts Clinical Trials
Other Boston Clinical Trials
Safety and Tolerability Study of FPTI in Patients With Leukemia
|
|
|
|
|
|
|
|
